Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents in patients with multivessel coronary artery disease compared to coronary artery bypass surgery five-years after intervention

Catheterization and Cardiovascular Interventions

Volumn 84, Issue 7, 2014, Pages 1029-1039

  Krenn, Lisa ^a   Kopp, Christoph ^a   Glogar, Dietmar ^a   Lang, Irene M ^a   Delle Karth, Georg ^a   Neunteufl, Thomas ^a   Kreiner, Gerhard ^a   Kaider, Alexandra ^a   Bergler Klein, Jutta ^a   Khorsand, Aliasghar ^a   Nikfardjam, Mariam ^a   Laufer, Günther ^a   Maurer, Gerald ^a   Gyöngyösi, Mariann ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Coronary artery bypass surgery; Cost benefit; Drugeluting stent; Follow up study; Percutaneous coronary intervention

Indexed keywords

PACLITAXEL;

ACUTE HEART INFARCTION; AGED; ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DRUG ELUTING STENT; FEMALE; HEALTH CARE COST; HEART DISEASE; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PACLITAXEL ELUTING STENT; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PROSPECTIVE STUDY; TREATMENT OUTCOME; ADULT; COMPARATIVE STUDY; CORONARY ARTERY BYPASS GRAFT; ECONOMICS; FOLLOW UP; HOSPITAL COST; MIDDLE AGED; PROCEDURES; TIME FACTOR;

ADULT; AGED; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; COST-BENEFIT ANALYSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HOSPITAL COSTS; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84912028477     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.25397     Document Type: Article

References (25)

1. Berger PB, Velianou JL, Aslanidou Vlachos H, Feit F, Jacobs AK, Faxon DP, Attubato M, Keller N, Stadius ML, Weiner BH, Williams DO, Detre KM; BARI Investigators. Survival following coronary angioplasty versus coronary artery bypass surgery in anatomic subsets in which coronary artery bypass surgery improves survival compared with medical therapy. Results from the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol 2001;38:1440-1449.
2. Legrand VMG, Serruys PW, Unger F, van Hout BA, Vrolix MC, Fransen GM, Nielsen TT, Paulsen PK, Gomes RS, de Queiroze Melo JM, Neves JP, Lindeboom W, Backx B; Arterial Revascularization Therapy Study (ARTS) Investigators. Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation 2004;109:1114-1120.
3. Macaya C, Garcia-Garcia HM, Colombo A, Morice MC, Legrand V, Kuck KH, Sheiban I, Suttorp MJ, Carrie D, Vrolix M, Wittebols K, Stoll HP, Donohoe D, Bressers M, Serruys PW. One-year results of coronary revascularization in diabetic patients with multivessel coronary artery disease.Sirolimus stent vs. coronary artery bypass surgery and bare metal stent: Insights from ARTS-II and ARTS-I. EuroIntervention 2006;2:69-76.
4. The SoS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery Trial): A randomised trial. Lancet 2002;360:965-970.
5. Yock CA, Boothroyd DB, Owens DK, Garber AM, Hlatky MA. Cost-effectiveness of bypass surgery versus stenting in patients with multivessel coronary artery disease. Am J Med 2003;115: 382-389.
6. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R; RAVEL Study Group. Randomized study with the sirolimus-coated BX Velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
7. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
8. Eisenstein EL, Leon MB, Kandzari DE, Mauri L, Edwards R, Kong DF, Cowper PA, Anstrom KJ; ENDEAVOR III Investigators. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized controlled trial of the Medtronic Endeavor drug [ABT-578]-eluting coronary stent system versus the Cypher sirolimus-eluting coronary stent system in de novo native coronary artery lesions). JACC Cardiovasc Interv 2009;2:1199-1207.
9. Serruys PW, Onuma Y, Garg S, Vranckx P, De Bruyne B, Morice MC, Colombo A, Macaya C, Richardt G, Fajadet J, Hamm C, Schuijer M, Rademaker T, Wittebols K, Stoll HP; ARTS II Investigators. 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimuseluting stent in the treatment of patients with multivessel de novo coronary artery lesions. J Am Coll Cardiol 2010;55: 1093-1101.
10. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Stahle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr F. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009;360: 961-972.
11. Magnuson EA, Farkouh ME, Fuster V, Wang K, Vilain K, Li H, Appelwick J, Muratov V, Sleeper LA, Boineau R, Abdallah M, Cohen DJ; FREEDOM Trial Investigators. Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: Results from the FREEDOM trial. Circulation 2013;127:820-831.
12. Hill RA, Boland A, Dickson R, Deundar Y, Haycox A, McLeod C, Mujica Mota R, Walley T, Bagust A. Drug-eluting stents: A systematic review and economic evaluation. Health Technol Assess 2007;11:iii-xi.
13. Goldman S, Sethi GK, Holman W, Thai H, McFalls E, Ward HB, Kelly RF, Rhenman B, Tobler GH, Bakaeen FG, Huh J, Soltero E, Moursi M, Haime M, Crittenden M, Kasirajan V, Ratliff M, Pett S, Irimpen A, Gunnar W, Thomas D, Fremes S, Moritz T, Reda D, Harrison L, Wagner TH, Wang Y, Planting L, Miller M, Rodriguez Y, Juneman E, Morrison D, Pierce MK, Kreamer S, Shih MC, Lee K. Radial artery grafts vs saphenous vein grafts in coronary artery bypass surgery: A randomized trial. JAMA 2011;305:167-174.
14. Willan AR, Briggs AH. Statistical Analyses of Costeffectiveness Data. Chichester: Wiley; 2006.
15. Cohen DJ, Lavelle TA, Van Hout B, Li H, Lei Y, Robertus K, Pinto D, Magnuson EA, McGarry TF, Lucas SK, Horwitz PA, Henry CA, Serruys PW, Mohr FW, Kappetein AP. Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with left main or threevessel coronary artery disease: One-year results from the SYNTAX trial. Catheter Cardiovasc Interv 2012;79:198-209.
16. Birim O, Bogers AJ, Kappetein AP. Cost effectiveness of coronary revascularisation. EuroIntervention 2010;5:763-767.
17. Filion KB, Roy AM, Baboushkin T, Rinfret S, Eisenberg MJ. Cost-effectiveness of drug-eluting stents including the economic impact of late stent thrombosis. Am J Cardiol 2009;103:338-344.
18. Groeneveld PW, Suh JJ, Matta MA. The costs and quality-oflife outcomes of drug-eluting coronary stents: A systematic review. J Interv Cardiol 2007;20:1-9.
19. Gyeongyeosi M, Christ G, Lang I, Kreiner G, Sochor H, Probst P, Neunteufl T, Badr-Eslam R, Winkler S, Nyolczas N, Posa A, Leisch F, Karnik R, Siostrzonek P, Harb S, Heigert M, Zenker G, Benzer W, Bonner G, Kaider A, Glogar D. 2-year results of the AUTAX (Austrian Multivessel TAXUS-Stent) registry. JACC Cardiovasc Intervent 2009;2:718-727.
20. Hoffman SN, TenBrook JA, Wolf MP, Pauker SG, Salem DN, Wong JB. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: One- To eight-year outcomes. J Am Coll Cardiol 2003;41:1293-1304.
21. Rastan AJ, Boudriot E, Falk V, Kappetein AP, Borger MA, Serruys PW, Schuler G, Mohr FW. Frequency and pattern of de-novo three-vessel and left main coronary artery disease; insights from single center enrolment in the SYNTAX study. Eur J Cardiothorac Surg 2008;34:376-382.
22. Weintraub WS, Grau-Sepulveda MV, Weiss JM, O'Brien SM, Peterson ED, Kolm P, Zhang Z, Klein LW, Shaw RE, McKay C, Ritzenthaler LL, Popma JJ, Messenger JC, Shahian DM, Grover FL, Mayer JE, Shewan CM, Garratt KN, Moussa ID, Dangas GD, Edwards FH. Comparative effectiveness of revascularization strategies. N Engl J Med 2012;366:1467-1476.
23. Chen SL, Chen JP, Mintz G, Xu B, Kan J, Ye F, Zhang J, Sun X, Xu Y, Jiang Q, Zhang A, Stone GW. Comparison between the NERS (New Risk Stratification) score and the SYNTAX (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) score in outcome prediction for unprotected left main stenting. JACC Cardiovasc Interv 2010;3: 632-641.
24. Kip KE, Hollabaugh K, Marroquin OC, Williams DO. The problem with composite end points in cardiovascular studies: The story of major adverse cardiac events and percutaneous coronary intervention. J Am Coll Cardiol 2008;51:701-707.
25. Kim YH, Park DW, Kim WJ, Lee JY, Yun SC, Kang SJ, Lee SW, Lee CW, Park SW, Park SJ. Validation of SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) score for prediction of outcomes after unprotected left main coronary revascularization. JACC Cardiovasc Interv 2010;3:612-623.